secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001829126-23-006020
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan sells addiction product portfolio to Fedson for $2M in cash and notes
---------------------------------------------------------------------------

- Total consideration of $2M: $500k cash at closing, $500k note due Oct 1, 2023, $1M note due Jan 1, 2024.
- Assets sold include Probuphine and Nalmefene implant programs (ProNeura drug delivery technology).
- Sale closed September 1, 2023; buyer Fedson delivered a principal guaranty for both notes.
- Pro forma shows estimated pre-tax gain of $1.9M for H1 2023 and $1.9M for FY 2022.
- Company had only $105k cash pre-sale; proceeds significantly improve liquidity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912623006020/0001829126-23-006020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912623006020/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-006020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer